Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...
The complement pathway is a regulated cascade of proteins that supports or complements (hence the name) the activity of antibodies and phagocytes in clearing infections. The pathway comprises three ...
AJMC ®: How has treatment of complement-driven diseases changed since 2007, when the first complement inhibitor, eculizumab, was approved? SMITH: The development of eculizumab followed our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback